An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study.

Olaparib is a potent inhibitor of poly(ADP-ribose) polymerase (PARP)-1, 2, and 3 with potential activity in endometrial cancer (EC). In this window-of-opportunity trial, women with operable type 1 EC received olaparib oral tablets (300 mg) twice daily for 28 days before surgery. The primary objective was to evaluate the effects of olaparib on EC in tissue samples taken at baseline and at treatment completion. Signal of activity was defined as significant changes in the expression of the cell cycle-related proteins cyclin D1, Ki67, and cleaved caspase-3. A total of 31 patients were included in the biomarker analysis. The median time of olaparib exposure was 24 days (1–39). Significant inhibition was found for cyclin D1 (p < 0.01), but not for Ki67 and active caspase 3 immunostaining. PARP-1 levels positively correlated with cyclin D1 levels (rho = 0.661, p = 0.0001). Both PARP-1 and cyclin D1 levels were significantly lower (p = 0.022 and p = 0.004, respectively) in patients with ARID1A[−] tumors than ARID1A[+] tumors. A significant relationship between plasma olaparib concentrations and decreased GLUT1 activity was observed (r = −0.5885; p < 0.05). Drug-related toxicity consisted mostly of gastrointestinal and grade 1 or 2 adverse events. Olaparib reduced expression of cyclin D1, which positively correlated with PARP-1 levels. This effect was more evident in ARID1A-deficient tumors. Olaparib further induced inhibition of GLUT1 plasma activity. Our findings could have noteworthy implications in predicting which patients with EC would benefit from olaparib-based strategies. • A window-of-opportunity trial to explore olaparib in endometrioid cancer. • Cyclin D1 expression is reduced by olaparib in a PARP-1 level-dependent manner. • In the ARID1A[−] tumors, PARP-1 and cyclin D1 were significantly lower compared to ARID1A[+]. • Olaparib induced GLUT1 inhibition in an olaparib concentration-dependent manner. [ABSTRACT FROM AUTHOR]